Merck & Co., Inc. (NYSE:MRK) Releases Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13, FiscalAI reports. The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period last year, the company earned $2.13 earnings per share. Merck & Co., Inc. updated its FY 2026 guidance to 2.660-2.760 EPS.

Here are the key takeaways from Merck & Co., Inc.’s conference call:

• Merck raised and narrowed its 2026 revenue outlook to $66.3 billion–$67.3 billion, while maintaining confidence in continued growth driven by oncology, animal health, and newer product launches.
• New and expanding products showed strong momentum, including WINREVAIR sales up 75%, WELIREG sales up 67%, and CAPVAXIVE sales up 40%; LIPFENDRA also received FDA approval as the first oral PCSK9 inhibitor.
• Pipeline de-risking accelerated, with positive Phase III results for sac-TMT in endometrial cancer and tulisokibart in ulcerative colitis, while weekly oral HIV-treatment data and multiple upcoming regulatory milestones support Merck’s projected long-term growth opportunities.
• Second-quarter reported EPS was a loss of $0.13, including a $2.31-per-share one-time charge tied to the Terns acquisition; Merck also expects U.S. KEYTRUDA growth to moderate, an OHTUVAYRE sales unwind in the third quarter, and higher inventory reserves to pressure margins.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock traded up $1.97 during mid-day trading on Wednesday, reaching $129.97. The company had a trading volume of 2,294,753 shares, compared to its average volume of 10,763,800. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The company has a 50 day moving average of $123.45 and a 200-day moving average of $118.78. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $135.05. The firm has a market cap of $321.00 billion, a price-to-earnings ratio of 36.61, a PEG ratio of 5.07 and a beta of 0.19.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Hedge Funds Weigh In On Merck & Co., Inc.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. during the 4th quarter worth approximately $26,000. IFC & Insurance Marketing Inc. bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at $31,000. Safe Harbor Fiduciary LLC bought a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $32,000. Gilpin Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $32,000. Finally, Wealth Watch Advisors INC bought a new position in shares of Merck & Co., Inc. in the third quarter valued at about $34,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MRK has been the subject of several recent analyst reports. UBS Group increased their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. Scotiabank boosted their price objective on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, June 30th. Citigroup assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price target on the stock. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Thirteen analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $134.56.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q2 results exceeded expectations: Merck reported revenue of $16.61 billion, above the $16.37 billion consensus, while its adjusted loss of $0.13 per share was narrower than the expected $0.26 loss. Revenue rose 5.1% year over year, led by oncology products and newer launches. Merck posts better-than-expected second-quarter results on Keytruda strength
• Positive Sentiment: Keytruda franchise remains strong: Sales of the injectable version of Keytruda reportedly surpassed Wall Street expectations by more than $200 million, reinforcing demand for Merck’s leading cancer portfolio and its strategy for managing the eventual post-Keytruda transition. The Merck Product That Absolutely Demolished Wall Street’s Forecasts
• Positive Sentiment: 2026 sales outlook raised: Merck increased its full-year revenue guidance to $66.3 billion-$67.3 billion, supported by pipeline progress and growth from recently launched products. Guggenheim also raised its price target to $146 and maintained a Buy rating, implying further upside from current trading levels. MRK Q2 Earnings Call Puts Pipeline Progress in Focus
• Neutral Sentiment: Pipeline progress is mixed: Merck is evaluating tulisokibart in multiple indications, but discontinued its study in systemic sclerosis-associated interstitial lung disease. The setback is limited to one indication but highlights development risk as investors assess Merck’s post-KEYTRUDA growth prospects. MSD posts a victory and defeat for anti-TL1A
• Negative Sentiment: Profit outlook was reduced: Merck set 2026 EPS guidance at $2.66-$2.76, well below the $3.42 analyst consensus, primarily because of charges related to its Terns Pharmaceuticals acquisition. The company’s reported quarterly loss also compares unfavorably with year-ago earnings of $2.13 per share. Merck hikes revenue outlook but cuts profit guidance

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.